



ORIGINAL ARTICLE



WILEY

Basic and Translational Allergy Immunology

Butyrate as bioactive human milk protective component against food allergy

Lorella Paparo^{1,2,3} | Rita Nocerino^{1,2} | Elena Ciaglia⁴ | Carmen Di Scala^{1,2} | Carmen De Caro⁵ | Roberto Russo⁵ | Giovanna Trinchese⁶ | Rosita Aitoro¹ | Antonio Amoroso¹ | Cristina Bruno^{1,2} | Margherita Di Costanzo^{1,2} | Annalisa Passariello^{1,7} | Francesco Messina⁸ | Annalisa Agangi⁸ | Marcello Napolitano⁸ | Luana Voto¹ | Giusy Della Gatta^{1,2} | Laura Pisapia^{1,2} | Francesco Montella⁴ | Maria Pina Mollica⁶ | Antonio Calignano⁵ | Annibale Puca^{3,9} | Roberto Berni Canani^{1,2,3,10}

¹Department of Translational Medical Science, University of Naples Federico II, Naples, Italy

²ImmunoNutritionLab at the CEINGE-Biotecnologie Avanzate s.c.ar.l Research Center, University of Naples Federico II, Naples, Italy

³European Laboratory for the Investigation of Food-Induced Diseases, University of Naples Federico II, Naples, Italy

⁴Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Fisciano, Italy

⁵Department of Pharmacy, University of Naples Federico II, Naples, Italy

⁶Department of Biology, University of Naples Federico II, Naples, Italy

⁷Department of Pediatric Cardiology, Monaldi Hospital, Naples, Italy

⁸Neonatal Intensive Care Unit, "Betania" Evangelical Hospital, Naples, Italy

⁹Cardiovascular Research Unit, IRCCS MultiMedica, Milan, Italy

¹⁰Task Force for Microbiome Studies, University of Naples Federico II, Naples, Italy

Correspondence

Roberto Berni Canani, Chief of the Pediatric Allergy Program at the Department of Translational Medical Science; Chief of the ImmunoNutritionLab at CEINGE - Advanced Biotechnologies, University of Naples "Federico II" Via S. Pansini 5 80131 Naples, Italy.
Email: berni@unina.it

Abstract

Background: Food allergy (FA) is a growing health problem worldwide. Effective strategies are advocated to limit the disease burden. Human milk (HM) could be considered as a protective factor against FA, but its mechanisms remain unclear. Butyrate is a gut microbiota-derived metabolite able to exert several immunomodulatory functions. We aimed to define the butyrate concentration in HM, and to see whether the butyrate concentration detected in HM is able to modulate the mechanisms of immune tolerance.

Methods: HM butyrate concentration from 109 healthy women was assessed by GS-MS. The effect of HM butyrate on tolerogenic mechanisms was assessed in *in vivo* and *in vitro* models.

Results: The median butyrate concentration in mature HM was 0.75 mM. This butyrate concentration was responsible for the maximum modulatory effects observed in all experimental models evaluated in this study. Data from mouse model show that in basal condition, butyrate up-regulated the expression of several biomarkers of gut barrier integrity, and of tolerogenic cytokines. Pretreatment with butyrate significantly reduced allergic response in three animal models of FA, with a stimulation of tolerogenic cytokines, inhibition of Th2 cytokines production and a modulation of oxidative stress. Data from human cell models show that butyrate stimulated human beta defensin-3, mucus components and tight junctions expression in human enterocytes, and IL-10, IFN- γ and FoxP3 expression through epigenetic mechanisms in PBMCs from FA children. Furthermore, it promoted the precursors of M2 macrophages, DCs and regulatory T cells.

Conclusion: The study's findings suggest the importance of butyrate as a pivotal HM compound able to protect against FA.

Lorella Paparo and Rita Nocerino equally contributed to this paper.

© 2020 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd


This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Funding information

Italian Ministry of Health, Grant/Award Number: PE-2011-02348447 and RF-2011-02348194; Cariplo Foundation, Grant/Award Number: 2016-0874; Italian Ministry of the University and Scientific Research, Grant/Award Number: PRIN-20157ATSLF_009; Umberto Veronesi Foundation, Grant/Award Number: FUV 2017 cod.1072, FUV 2018 cod.2153 and FUV 2019 cod.2798

KEYWORDS

breast milk, immune tolerance, short-chain fatty acids, tolerogenic mechanism

**GRAPHICAL ABSTRACT**

Human milk contains a significant level of the short-chain fatty acid butyrate. At concentration detectable in human milk, butyrate effectively modulates several tolerogenic mechanisms involved in the protection against food allergy. The protective role of human milk against food allergy could be related, at least in part, to the presence of an effective concentration of butyrate

1 | INTRODUCTION

Food allergy (FA) is a potentially deadly immune reaction triggered by the ingestion of food protein antigens.¹ Over the past two decades, the prevalence and severity of childhood FA have increased with significant direct medical costs for the healthcare systems of industrialized countries and even greater costs for families of food-allergic children.² In light of this changing FA scenario, effective preventive and therapeutic strategies are of substantial clinical and socioeconomic value.

Studies support the hypothesis that altered microbial exposure and colonization in early life influence the occurrence of FA.^{3,4}

Differential gut microbiota structures confer protection or susceptibility to FA by modulating the tolerogenic mechanisms.⁴ Several protective functional effects of gut microbiota against FA derive from the action of its metabolites.⁵ Growing evidence demonstrates that gut microbial metabolites, mainly short-chain fatty acids (SCFAs), exert immunomodulatory functions that are beneficial to

the host and play a pivotal role in shaping the immune system.^{5,6} Among the SCFAs, butyrate has emerged since the discovery of its role in driving T regulatory cell (Treg) differentiation and maintenance of gut homeostasis.⁷⁻¹¹ After absorption into enterocytes, butyrate enters the circulation and modulates immune functions in peripheral tissues.¹² Via the inhibition of histone deacetylases (HDAC) and activation of G protein-coupled receptors (GPCR) on epithelial and immune cells, butyrate influences gene expression and inflammatory responses.¹³

Despite no conclusions can be made about the role of breastfeeding in either preventing or delaying the onset of FA, it has been thought that immunologic components of human milk (HM) may modify induction of immune tolerance and decrease the risk of allergic diseases.^{14,15}

Human milk is a complex nutritional fluid that contains several compounds able to provide health benefits.¹⁵ Accumulated data suggest that a wide range of bioactive factors such as the macro- and micronutrients, microbial components, and metabolites present in

HM can influence infant immune system maturation.¹⁶ Considering its pivotal role in immune tolerance, it could be relevant to define the butyrate content in HM and its potential preventive role against FA. A preliminary study examined HM as a potential source of butyrate for neonates with a different content than infant formula,¹⁷ but the butyrate levels in HM remain poorly defined.

The aims of this study were to evaluate the concentration of butyrate in HM and to determine whether this concentration is able to effectively modulate the main tolerogenic mechanisms involved in the protection against FA.

2 | MATERIALS AND METHODS

2.1 | Study design

This study was designed to evaluate butyrate concentration in HM (HM butyrate) and investigate its potential to exert a protective role against FA. First, we defined HM butyrate concentration in a cohort of healthy lactating women. Subsequently, we explored the tolerogenic effects of HM butyrate in different animal models of FA and in human enterocytes. Finally, we assessed the tolerogenic action in peripheral blood mononuclear cells (PBMCs) from healthy donors and FA children. The study was approved by the Ethics Committee of the University of Naples "Federico II," Naples, Italy.

Healthy mothers (aged 21-42 years) who participated in this study were enrolled after full-term singleton pregnancy at the Betania Evangelical Hospital (Naples, Italy), and written informed consent was obtained from all of the participants. The use of antibiotics or gastric acidity inhibitors or pre-/pro-/symbiotics in the previous 6 months; and the presence of infections, allergic diseases, inflammatory bowel diseases, autoimmunity, celiac disease, food intolerances, genetic and metabolic disorders, malformations of the gastrointestinal (GI) tract, and history of surgical procedures involving the GI tract were excluded in all of the enrolled subjects.

Human milk samples were obtained at 3 days (colostrum), and monthly for the first 5 months postpartum. HM samples (2 mL) were collected at the beginning of lactation by either manual or electric breast pump into sterile tubes, as previously described.¹⁸ Samples were immediately frozen and then stored at -80°C until analysis. For each enrolled subject, anamnestic, demographic, clinical, and laboratory data were recorded in a data collection sheet. The sampling procedures applied ensured that breastfeeding had been well-established and that the baby was thriving.

2.2 | Determination of butyrate concentration in human milk samples

Butyrate extraction from HM was conducted as previously described.¹⁹ All samples from -80°C were defrosted at 4°C for 12 hours and then inverted 10 times to mix at RT. 1 mL of each sample was acidified with 40 μL of H_3PO_4 85%(w/v), vortexed for

5 minutes, and sonicated for 10 minutes at 40 KHz immersed in an ice bath (Branson 2800 Ultrasonic). 1 mL of ethyl acetate was added, vortexed for 10 minutes, and centrifuged (12 000 g for 45 minutes). Finally, it was taken from the supernatant (organic phase, of about 1 mL) with a Pasteur pipette and placed in a new glass tube for gas chromatography-mass spectrometry (GC-MS) analysis. The GC column was an Agilent 122-7032ui (DB-WAX-U; Agilent Technologies) of 30 m, internal diameter of 0.25 mm, and film thickness of 0.25 μm . The GC was programmed to achieve the following run parameters: initial temperature of 50°C , hold of 1 minutes, ramp of 10°C minutes^{-1} up to a final temperature of 180°C , total run time of 20 minutes, gas flow of 70 mL minutes^{-1} splitless to maintain 12.67 p.s.i. column head pressure, and septum purge of 2.0 mL minutes^{-1} . Helium was the carrier gas (1.5 mL minutes^{-1} constant). Parameters of mass spectrometer were as follows: source at 230°C and MS Quad at 150°C . The GraphPad PRISM 5 program was used to determine the concentration in mM. The data were inserted in the "XY" form in which in the "X" frame the values of the straight concentration-response were reported, while in the "Y" box the values of the area under the curve (AUC) related to the peaks obtained from the mass gas were reported. The AUC values of the single samples (obtained from the mass gas) were interpolated with the line X (concentration-response) to determine the corresponding mM.

2.3 | Animal models

For all experiments, three-week-old female C3H/HeJ mice were purchased from Charles River Laboratories (Calco). The mice were housed in an animal facility under a 12-L:12-D lighting cycle, with a $20^{\circ}\text{-}24^{\circ}\text{C}$ range of ambient temperature and 40%-70% relative humidity. The mice were acclimated to their environment for 1 week before the experiments. Each experiment was littermate-controlled, and the mice were co-housed throughout. The mice were fed a commercially available standard diet (Teklad Rodent Diet 8604; Harlan). All of the procedures involving the animals were conducted in adherence to the NIH Guide for the Care and Use of Laboratory Animals and in accordance with the Institutional Guidelines and complied with the Italian DL No. 116 of January 27, 1992, of the Italian Ministry of Health and associated guidelines in the European Communities Council Directive of November 24, 1986 (86/609/ECC), and approved by the Institutional Committee on the Ethics of Animal Experiments (CSV) of the University of Naples Federico II and by the Italian Ministry of Health (Protocol No. 2012-0024683).

2.3.1 | Evaluation of butyrate effects in basal condition on gut barrier and on cytokine response

The animals were divided into two groups: (a) control mice ($n = 4$), receiving water as vehicle; (b) treated mice ($n = 4$), receiving butyrate

once daily (oral administration of 30 mg/kg of body weight). After 14 days, mice were killed, and ileum, jejunum, and colon, spleen, and mesenteric lymph nodes (MLN) were removed and stored at -80°C .

2.3.2 | Measurement of gut permeability *in vivo*

To investigate intestinal permeability, we used 4000 Da FITC-labeled dextran as previously described.²⁰ FITC-dextran concentration was determined by spectrophotometry (HTS-7000 Plus Plate Reader; Perkin Elmer).

2.3.3 | Gut barrier biomarkers and cytokine response

Total cellular RNA was extracted from ileum, jejunum, and colon, spleen, and MLN with TRIzol reagent (Gibco BRL). RNA (1 μg) was reverse-transcribed at 37°C in cDNA with a High-Capacity RNA-to-cDNA™ Kit (Life Technologies) according to the manufacturer's instructions. Quantitative real-time PCR (qRT-PCR) analysis was performed with the TaqMan Gene Expression Assay Kit (Applied Biosystems) according to the manufacturer's instructions. The TaqMan probe for IL-22, a marker of intestinal permeability, zonula occludens 1 (ZO-1), and occludin, proteins involved in the regulation of barrier integrity, mucin 2 (Muc2), protein involved in the regulation of mucus thickness, and the cytokines Th2 (IL-4, IL-5, IL-13), Th1 (IFN- γ), and IL-10 were inventoried and tested by Applied Biosystems manufacturing facility (QC). Samples were run in duplicate at 95°C for 15 seconds and 60°C for 1 minute using an ABI Prism 7900 HT Sequence Detection System (Applied Biosystems). After a hot start, the amplification protocol was 40 cycles of 30 seconds of denaturation at 95°C , 30 seconds of annealing at 60°C , and 1 minutes of elongation at 72°C . Data analysis was performed with the comparative threshold cycle (CT) method. We used the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene to normalize the level of mRNA expression.

2.3.4 | Lymphocyte isolation and Treg analysis by flow cytometry

To enrich mononuclear cell population and remove dead cells and red blood cell from mice spleens and MLN, we used a gradient method by a high-density with Ficoll solution as previously described.²¹⁻²³ The mononuclear cells, floating on top of the high-density solution, were collected and used for FACS analysis. MLN were isolated from colon as previously described.²⁴ Colon was removed, cleared of mesenteric fat, flushed with PBS to remove feces, opened longitudinally, and cut into small pieces. The small pieces were transferred into PBS containing 5mM EDTA (Thermo Fisher) and incubated at 37°C for 20 minutes in a shaking incubator. Following this, the EDTA solution was removed and incubated in RPMI 1640 supplemented

with 4% fetal calf serum (FCS; Lonza, Visp, Switzerland), 0.5 mg/mL collagenase D (Roche), 0.5 mg/mL dispase (Roche), and 40 μg /mL DNase (Sigma) at 37°C for 40 minutes in a shaking incubator. The digested tissue was passed through a cell strainer, washed with RPMI/4% FCS, resuspended in 40% Percoll (GE Healthcare), and overlaid onto 80% Percoll. Percoll gradient was centrifuged at 1200 g for 35 minutes. Cells were collected at the interface of the Percoll layers, washed with RPMI/4% FCS, and used immediately for FACS analysis. Tregs from different tissue were identified as CD4+/CD25+/FoxP3+ cells by flow cytometry analysis. The staining was performed using Mouse Regulatory T cell Staining Kit (eBioscience), and the results were analyzed by BD FACSCanto II flow cytometer and DIVA software (BD).

2.3.5 | Food allergen sensitization and challenge

The experimental design is shown in Figure 3A. Briefly, 2 weeks prior to sensitization, the mice were administered 30 mg/kg/day of sodium butyrate (Sigma-Aldrich) by oral gavage and continued throughout the study. The control animals received PBS only. After 14 days, the mice were sensitized orally using a blunt needle. On days 0, 7, 14, 21, and 28, they were administered 20 mg of beta-lactoglobulin (BLG) (Sigma-Aldrich), 1 mg of ovalbumin (OVA) (Sigma-Aldrich), or 12 mg of peanuts extract (PN) (kindly provided by Prof. C. Nagler, University of Chicago, USA) mixed with 10 μg cholera toxin (CT) as adjuvant. The control mice received CT only. One week after the final sensitization, two doses of 50 mg BLG, 5 mg OVA, or 36 mg PN each were administered 30 minutes apart via intragastric gavage. Core body temperature was measured prior to allergen challenge and every 5 minutes after the first challenge until at least 30 minutes after the second challenge using a rectal probe (Mitutoyo). Anaphylaxis symptoms were scored by an investigator blind to the study group assignment 1 hour after oral challenge: 0 = no symptom; 1 = scratching and rubbing around the nose and head; 2 = reduced activity; 3 = activity after prodding and puffiness around the eyes and mouth; 4 = no activity after prodding, labored respiration, and cyanosis around the mouth and the tail; and 5 = death. Serum was collected 1 hour after the second challenge to measure the mouse mast cell protease-1 (mMCP-1) levels. The spleen and serum were collected 24 hours after challenge for splenocyte culture and antibody measurements.

2.3.6 | ELISAs

mMCP-1 was quantified in the serum collected 1 hour after challenge according to the manufacturer's protocol (eBioscience, Thermo Fisher Scientific). BLG/PN-specific ELISAs were performed using protocols modified from Ref. 20 Briefly, plates were coated overnight at 4°C with 100 μg /mL BLG/PN in 100 mM carbonate-bicarbonate buffer (pH 9.6). Plates were blocked for 2 hours at room temperature with 3% BSA. Samples were added in

1% BSA and incubated overnight at 4°C. Assays were standardized with BLG/PN-specific antibodies (IgE) purified from mice immunized with BLG + alum or PN + alum on a CNBr-Sepharose affinity column. Secondary antibody (biotin anti-IgE; BD Pharmingen) was added at a 1:500 dilution overnight at 4°C. On the third day, the plate was incubated with streptavidin-HRP (Thermo Fisher) for 1 hour at room temperature and developed with TMB (Sigma-Aldrich) and 15 minutes was allowed for the development of colorimetric reactions.

Absorbance was read at a wavelength of 450 nm in a microplate reader. OVA-specific IgE was measured using commercially available ELISA Kit (eBioscience).

2.3.7 | Spleen culture and cytokine measurement

Single-cell suspensions were prepared from spleens harvested 24 hours after challenge. Cells were plated at 2×10^5 cells/well with the media alone, 1 µg/mL anti-CD3 (clone 2C11), or 200 µg/mL BLG/OVA/PN and incubated at 37°C for 72 hours. After 72 hours, the plates were frozen at -20°C. Supernatant IL-4, IL-13, IL-10, and INF-γ concentrations were measured using commercially available ELISA Kits (eBioscience).

2.3.8 | Preparation of isolated mitochondria and polarographic measurement of respiration

After removal, the livers were finely minced and washed in a medium containing 220 mM mannitol, 70 mM sucrose, 20 mM-N'-(2-hydroxyethyl) piperazine-N-2-ethanesulfonic acid (HEPES) (pH 7.4), 1 mM EDTA, and 0.1% (w/v) fatty acid-free bovine serum albumin (BSA). The protocol was performed as previously described.²⁵

2.3.9 | Determination of mitochondrial enzymatic activities and H₂O₂ release

For the determination of aconitase specific activity, we used protocols previously described.²⁶ The level of aconitase activity measured equals active aconitase (basal level). Aconitase inhibited by ROS in vivo was reactivated so that total activity could be measured by incubating mitochondrial extracts in a medium containing 50 mM dithiothreitol, 0.2 mM Na₂S, and 0.2 mM ferrous ammonium sulfate.²⁶ The rate of mitochondrial H₂O₂ release was measured at 30°C following the protocol previously described.²⁷ Determinations were carried out spectrophotometrically (550 nm) at 25°C, by monitoring the decrease in the reduction rate of cytochrome c by superoxide radicals, generated by the xanthine-xanthine oxidase system. One unit of SOD activity is defined as the concentration of enzyme that inhibits cytochrome c reduction by 50% in the presence of xanthine + xanthine oxidase.²⁸

2.4 | Human enterocyte cell lines

Human enterocyte cell lines Caco-2 and HT-29 were used (American Type Culture Collection). Caco-2 and HT29 cells were separately grown as previously described.²⁹ For the following experiments, monocultures of Caco-2 and HT-29 cells were seeded on the apical chamber of Transwell inserts with different proportions of 1:0 and grown in 12-well Transwell plates with a final density of 1×10^5 cells/cm² in each insert to obtain a co-culture, as previously described.²⁹ Cells were maintained in the same conditions and allowed to grow for 15 days with medium changes every other day. All the experiments were performed in triplicate and repeated twice.

2.4.1 | Tolerogenic biomarker analysis in human enterocytes

At full confluence (15-21 days), Caco-2/HT-29 cells were stimulated for 48 hours with or without butyrate (Sigma-Aldrich) at different doses (0.1; 0.5; 0.75; 1; 2 mM). Afterward, the supernatants were harvested and stored at -80°C for further use. Cells were used for RNA extraction to perform real-time PCR experiments. The concentration of beta-defensin 3 (HBD-3) in the supernatants was measured using a commercially available ELISA Kit specific for human HBD-3 (MyBioSource) with a detection limit of 11.3 pg/mL. The ELISA was conducted according to the manufacturer's recommendations. ZO-1, occludin, Muc2, and mucin 5AC (Muc5AC) and FoxP3 gene expression analysis were performed as described above. The measurement of the mucus thickness was performed as previously described.³⁰

2.4.2 | HDAC activity assay

To assess HDAC activity, human enterocytes were treated with 10 nmol/L TSA (Sigma-Aldrich) and with butyrate (Sigma-Aldrich) at different doses (0.1; 0.5; 0.75; 1; and 2 mM) for 48 hours. The cell nuclear extracts (3×10^7 cells/well in 10 mL of culture medium) were prepared by using the Nuclei EZ Prep Kit (Sigma-Aldrich) and quantified by using the Micro BCA Protein Assay Kit. HDAC activity was measured with the EpiQuik HDAC Activity/ Inhibition Assay Kit (EpiGentek), according to the manufacturer's instructions.

2.5 | Peripheral blood mononuclear cell stimulation

Four otherwise healthy children (Caucasian male, age 24 months with negative clinical history for any allergic conditions and not at risk of atopic disorders), referred to the Department of Translational Medical Science at the University of Naples "Federico II" because of minimal surgical procedure, and twelve children with challenge-proven IgE-mediated FA (4 with cow's milk allergy, 4 with peanut allergy, and 4 with hen's egg allergy; all Caucasian male, aged 24 months), were recruited.

The concomitant presence of other conditions was excluded in all FA subjects by the result of a full anamnestic and clinical evaluation performed at the center by experienced pediatricians and pediatric allergists. The main features of the study population are reported in Table S1. Patients and control subjects donated a venous blood samples in heparin tubes (12 mL), after written informed consents collected by the parents/tutors. PBMCs were isolated using the Ficoll-Histopaque (Sigma-Aldrich) method, as described previously.²¹⁻²³ PBMCs were seeded at 2×10^5 /mL and grown in RPMI medium 1640 (Gibco) supplemented with 10% FCS (Lonza), 1% L-glutamine (Lonza), and 1% penicillin/streptomycin (Lonza). Cells were stimulated in the presence or in the absence of butyrate (Sigma) at the dose of 0.75 mM or with specific allergen: We used OVA for hen's egg allergy, BLG for cow's milk allergy, and PN for peanut allergy (100 µg/mL). Cells were cultured at 37°C in a water-saturated atmosphere consisting of 95% air and 5% CO₂ for 24 hours. After stimulation, the supernatants were collected and the cells were washed and harvested for CD4+ T-cell isolation.

2.5.1 | Cell viability assay and apoptosis rate evaluation

Peripheral blood mononuclear cell viability assays were assessed using MTT (the bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium) (Sigma), as previously described.³⁰ PHA (10 µg/ml) was used as a positive control. Cell apoptosis rates were measured using Annexin V Apoptosis Detection Kit FITC (Invitrogen, Carlsbad, California, USA) according to the manufacturer's protocol. In brief, after washing the collected cells with PBS were incubated with $1 \times$ Annexin V binding buffer.

Then, 5×10^5 cells were stained with Annexin V-FITC for 10 minutes at room temperature in the dark and before reading to flow cytometer was added propidium iodide 5 µg/mL. Each sample was acquired and analyzed using BD FACSCanto II Flow Cytometer and DIVA software (BD).

2.5.2 | Measurement of IL-4, IL-5, IL-13, IL-10, and IFN-γ culture medium concentration

The concentrations of IL-4 and IL-10 were measured in supernatants with a Human IL-4 and IL-10 ELISA Kit (Boster Biological Technology, Ltd.) according to the type of stimulation and stimulant. Human IL-5, IL-13, and IFN-γ ELISA (BioVendor) were used to detect the IL-5, IL-13, and IFN-γ concentrations. Absorbance was read at 450 nm.

2.5.3 | Isolation of naïve CD4+ T cells from PBMCs for flow cytometry and epigenetic analyses

Naïve CD4+ T cells were obtained by negative selection using the CD4+ T-Cell Isolation Kit II (Miltenyi Biotec) from stimulated PBMCs. Nontarget cells were labeled with a cocktail of biotin-conjugated

monoclonal antibodies (MicroBead Cocktail, Miltenyi Biotec), and the magnetically labeled nontarget T cells were retained on a column in the magnetic field of a separator (Miltenyi Biotec). This protocol produces > 95% pure CD4+ T cells, as tested by fluorescence-activated cell sorting analysis. Cells were resuspended at 2×10^6 cells/mL in RPMI-1640 culture medium (Gibco) supplemented with 10% FBS, penicillin/streptomycin (1%) (Lonza), L-glutamine (1%), sodium pyruvate (1%) (Lonza), and NEAA (1%) (Lonza). Cells were cultured at 37°C in complete medium at concentrations of 2×10^5 cells/ml in 24-well plate (Nunc). Naïve CD4+ T cells obtained were processed for flow cytometry assays and for DNA/RNA extraction. All experiments were performed in triplicate and repeated twice.

2.5.4 | DNA methylation analysis

One microgram of the DNA extracted from the naïve CD4+ T cells was modified with sodium bisulfite to convert all of the unmethylated but not the methylated cytosines to uracil. The bisulfite conversion was carried out using the EZ DNA Methylation Gold Kit (Zymo Research Co.) according to the manufacturer's instructions. The converted DNA was stored at -20°C until use. Fully methylated DNA and fully unmethylated DNA (Merck Millipore) were used as the controls for the optimization of the assay conditions and to calculate the percent of methylation (0%-100%). The primers used for the DNA methylation analysis of IL-4, IL-5, IL-10, IFN-γ, and FoxP3 TSDR were previously reported elsewhere.^{21,22} High-resolution melting real-time PCR for methylation analysis was performed as described previously.^{21,22} Real-time PCR was performed with the LightCycler 480 instrument (Roche). The amplification program was described in previous studies.^{21,22}

The results of the methylation analysis were confirmed by direct sequencing (using the Sanger method modified as follows: ddNTPs labeled with four different fluorophores) and analyzed via capillary electrophoresis (the analytical specificity and sensitivity of the test were >99%).

2.5.5 | Generation and treatment of monocyte-derived dendritic cells (Mo-DCs)

To generate DCs, CD14+ monocytes were positively selected from PBMCs of healthy donors and IgE-mediated FA patients by immunomagnetic procedure (Miltenyi Biotec). Immature DCs were then obtained by culturing CD14+ cells at 10^6 cells/mL in RPMI 1640 (Invitrogen), 10% FCS (Lonza), 50 ng/mL GM-CSF, and 1000 U/mL IL-4 with or without butyrate (Sigma-Aldrich) as previously described.³¹

2.5.6 | Antibodies and flow cytometry

Single-cell suspensions from PBMCs were stained with mAb against human CD14 (HCD14; BioLegend), human CD206 (DCN228;




FIGURE 1 Butyrate concentrations in human milk. A, Individual dot plot of butyrate concentrations observed in the colostrum and in the mature human milk samples collected by 109 lactating healthy women, * $P < .001$. B, Longitudinal results of butyrate concentration during the first 5 mo of lactation. Data were analyzed using repeated-measures ANOVA test ($P < .05$)

Miltenyi Biotec), human/mouse CD11b (M1/70.15.11.5; Miltenyi Biotec), human CD1a (HI149; Miltenyi Biotec), human CD1a (HI149; Miltenyi Biotec), human CD86 (REA968; Miltenyi Biotec), human CCR7 (REA108; Miltenyi Biotec), human CD45 RA (T6D11; Miltenyi Biotec), CD4 (A161A1; BioLegend), and human CD103 (REA803; Miltenyi Biotec). After 20-minutes incubation at 4°C in the dark, cells were washed and resuspended in PBS for the FACS analysis. For each test, cells were analyzed using FACSVerse Flow Cytometer and DIVA software (BD Biosciences).

2.5.7 | Establishment of DC-T cell co-culture

To induce Treg differentiation in *in vitro*, butyrate-DCs and naïve CD4⁺ T cells were seeded into a round-bottomed 96-well plate in 200 μ L medium and then co-cultured further in 5% CO₂ at 37°C for 4 days. On day 5, cells were harvested and analyzed by FACSVerse Flow Cytometer for the definition of the most peculiar subsets among CD4⁺ T-cell compartment including effector memory (TEM; CD45RA-CCR7⁺), effector memory RA (TEMRA; CD45RA+CCR7⁻), naïve (TN; CD45RA+CCR7⁺), and central memory (TCM; CD45RA-CCR7⁺) T cells and Tregs. Specifically, the staining and enumeration of CD4⁺CD25⁺CD127^{dim}/^{neg} Tregs were performed by using the Treg Detection Kit (CD4/CD25/CD127) (Miltenyi Biotec), according to the manufacturer's instructions. In a new set of experiments, naïve CD4⁺ T cells were further exposed to the 0.75 mM of butyrate alone for 5 days and then stained with the Treg Detection Kit (CD4/CD25/CD127) (Miltenyi Biotec).

2.5.8 | Cell culture and pretreatment of immune cells from IgE-mediated FA patients

Prestimulated PBMCs, with 0.75 mM butyrate, were cultured in complete medium, with or without specific allergen (OVA for hen's egg allergy, BLG for cow's milk allergy, and PN for peanut allergy; 100 μ g/mL) for 24 hours. Then, CD14⁺ gated monocytes were assayed for the surface expression of CD86 or alternatively CD206 activation marker. At the end of the 7 days of culture, Mo-DC generated in the presence of butyrate was analyzed by flow cytometry

for detected CD1a or alternatively CD103⁺ expression. The polarization of naïve CD4⁺ T cells into different subtypes was evaluated at the end of the 5 days of culture in the presence of 0.75 mM of butyrate or after immature or 24-hours specific allergen (BLG, OVA, and PN)-stimulated butyrate-DC co-culture as previously described.³² All cell cultures were conducted at 37°C in humidified 5% CO₂ atmosphere.

2.6 | Statistical analysis

The Kolmogorov-Smirnov test was used to determine whether the variables were normally distributed. For the continuous variables, the groups were compared using the equality of means test. For each type of assay for the flow cytometric analysis, the data obtained from multiple experiments were calculated as mean \pm SD and analyzed using the two-tailed Student's *t* test for the independent groups or ANOVA test. The level of significance for all of the statistical tests was two-sided, $P < .05$. All of the data were collected in a dedicated database and analyzed by a statistician using SPSS software (SPSS Inc, version 23.0) and GraphPad Prism 7.0.

3 | RESULTS

3.1 | Butyrate concentration in human milk

A total of 109 healthy lactating women (all Caucasian, mean age: 31.6 ± 6.0 SD) consented to participate in this study and provided HM samples during the first 5 months of lactation.

Butyrate concentration was significantly higher in mature HM than in colostrum (Figure 1, panel A) and remained stable until the fifth month of lactation (Figure 1, panel B). Total butyrate concentration observed in HM samples from healthy women ranged from 0.15 to 1.93 mM (IQR: 0.43) in colostrum and 0.16 to 1.97 mM (IQR: 0.43) in mature milk. The median butyrate concentration in mature HM was 0.75 mM, suggesting that a fully breastfed infant could receive a daily dose of butyrate of approximately 30 mg/kg body weight. The same dose was adopted in the animal model.




FIGURE 2 Effects of HM butyrate in basal condition on gut barrier and on cytokine response. Four-week-old female C3H/HeJ mice were divided into two groups: (1) control mice ($n = 4$), receiving water as vehicle; (2) treated mice ($n = 4$), receiving oral butyrate once daily (30 mg/kg of body weight). After 14 d all mice were killed, and intestine, in particular ileum, jejunum, and colon, spleen, and mesenteric lymph nodes (MLN) were removed. A-E, Oral butyrate treatment elicited a significant reduction in gut permeability, measured by plasma FITC-dextran quantification, and increase in IL-22, occludin, ZO-1, and Muc2 expression. F-L, Oral butyrate treatment induced a significant reduction in IL-4, IL-5, and IL-13 and a significant increase in IFN- γ and IL-10 expression in MLN and spleen. M-N, CD4⁺/CD25⁺/FoxP3⁺ cell numbers were increased after butyrate treatment in mouse spleen MLN and colon. Data are representative of at least 2 independent experiments, reported as median with range, and analyzed using the unpaired t test. * $P < .05$




FIGURE 3 Preventive HM butyrate action against FA in the animal model. A, The experimental design of the food allergy mouse model. Four-week-old female C3H/HeJ mice ($n = 4$ in each group) were used in the FA animal model. Two weeks before first sensitization, oral gavage with 30 mg/kg/d of butyrate was started and continued throughout the study. The mice were sensitized orally on days 0, 7, 14, 21, and 28, with 20 mg of BLG, 1 mg of OVA, or 12 mg of PN mixed with 10 μ g cholera toxin (CT) as adjuvant. The control mice receive CT only. On day 35, the mice were challenged by gavage with BLG (50 mg), OVA (5 mg), or PN (36 mg). Anaphylaxis scores and rectal temperatures were assessed for 1 h after challenge, and blood samples were collected to measure mMCP-1 and sIgE. After 24 h, the mice were killed, and their serum and tissues were collected. Two independent experiments were performed. Oral butyrate treatment significantly reduced anaphylactic score (B), serum MCP-1 (C) and sIgE levels against BLG (D), OVA (E), and PN (F). Splenocytes from FA-sensitized mice were stimulated 1 μ g/mL of anti-CD3 (clone 2C11) or 200 μ g/mL BLG/OVA/PN and incubated at 37°C for 72 h. Butyrate inhibited IL-4 (G) and IL-13 (H) production and stimulated IL-10 (I) and IFN- γ (L) production in BLG-, OVA-, and PN-sensitized mice. H₂O₂ yield (M), SOD (N), and ROS-induced damage on aconitase activity (O) were measured in hepatic mitochondria. The mitochondrial ROS-induced dysfunction was proven by the higher mitochondrial H₂O₂ yield, higher SOD activity, and lower basal/total aconitase ratio observed in all FA-sensitized animals compared with the control group. Butyrate administration positively modulates the oxidative stress as demonstrated by the lower H₂O₂ release, the decreased SOD activity, and the reactivation of the aconitase enzyme in all treated groups compared with control animals. Data are representative of at least 2 independent experiments, reported as median with range, and analyzed using the unpaired *t* test. BLG, mice sensitized with β -lactoglobulin; CTRL, control mice; OVA, mice sensitized with ovalbumin; PN, mice sensitized with peanut extract. * $P < .05$; ** $P < .01$; *** $P < .001$

3.2 | Evaluation of butyrate effects in basal condition on gut barrier and on cytokine response in the animal model

To explore the regulatory role elicited by butyrate, at a median HM concentration (0.75 mM) on gut barrier we focused on gut permeability, IL-22, occludin, ZO-1, and Muc2, as biomarkers of gut barrier integrity. As showed in Figure 2, butyrate was able to reduce the gut

permeability and to modulate all these biomarkers throughout the intestinal tract with differences related to the intestinal segment evaluated. The regulatory action elicited by butyrate on gut barrier paralleled a significant regulation of cytokine expression in MLN and in spleen, consisting of a significant reduction in IL-4, IL-5, and IL-13 and a significant increase in IFN- γ and IL-10 expression (Figure 2, panels A-I). Finally, butyrate induced a significant increase in CD4+/CD25+/FoxP3+ cells (Tregs) in spleen, MLN, and colon (Figure 2).

3.3 | Preventive butyrate action against FA in the animal model

To determine whether the estimated daily dose of butyrate received by a breastfed infant could elicit a protective action against the onset of FA, we adopted three different animal models resembling the most common forms of FA in childhood: cow's milk allergy (CMA), hen's egg allergy, and peanut allergy. Mice sensitized with β -lactoglobulin (BLG), ovalbumin (OVA), or peanut extract (PN) showed a significantly higher anaphylactic symptom score and body temperature decrease compared with the control animals. Exposing the animals to an oral daily dose of 30 mg/kg of body weight of butyrate resulted in a significant inhibition of all of these parameters of allergic response (Figure 3, panel B). To determine whether the butyrate administration was effective in reducing local mucosal mast cell degranulation in sensitized mice, mMCP-1 serum concentrations were measured after oral challenge. mMCP-1 serum levels were significantly increased in BLG-, OVA-, and PN-sensitized mice compared with the control animals. However, butyrate caused a significant reduction in mMCP-1 concentration in the sensitized mice (Figure 3, panel C). According to these data, butyrate administration also caused a reduction in serum-specific IgE concentration (Figure 3, panels D-F).

To investigate the mechanisms underlying the effect of butyrate in reducing allergic response, the splenocyte cytokine production in BLG-, OVA-, and PN-sensitized mice was evaluated. It was evident that there was a significant decrease in the Th2 cytokines (IL-4 and IL-13) (Figure 3, panels G and H) and a significant increase in

the IFN- γ and IL-10 production compared with control animals after butyrate administration (Figure 3, panels I and L).

Recent evidence demonstrated that hepatic mitochondrial dysfunction and the consequent excessive generation of ROS are related to Th2 response in FA.³³ Oral butyrate (0.75 mM) significantly modulated the oxidative stress in all three FA animal models, reducing H₂O₂ release and superoxide dismutase activity (SOD) and reactivating the aconitase enzyme (Figure 3, panels M-O).

3.4 | Direct effects of butyrate on tolerogenic mechanisms in human enterocytes

Intestinal permeability and mucous layer exert a pivotal role in immune tolerance.³⁴ Dose-response and time-course experiments showed that HM butyrate stimulates the expression of tight junction (TJ) proteins, ZO-1 and occludin in human enterocytes. Interestingly, the maximal effective dose was 0.75 mM, equal to median concentration detected in mature HM (Figure 4, panels A and B). Similar results were observed for Muc2 and Muc5AC expression (Figure 4, panels C and D). Accordingly, 0.75 mM butyrate was also the maximal effective dose for the regulation of mucus layer thickness in human enterocyte (from 0.0 to 5.0 \pm 2 μ m; basal vs butyrate, $P < .05$). It has been demonstrated that HBD-3, an innate immunity peptide produced by human enterocytes, is involved in tolerogenic mechanisms through FoxP3+ T-cell induction.³⁵ We found that 0.75 mM butyrate was the maximal




FIGURE 4 Direct effect of butyrate on nonimmune and immune tolerogenic mechanisms in human enterocytes. Dose-response effects of butyrate (from 0.1 to 2 mM) after 48 h of stimulation in Caco-2/HT-29 cells. ZO-1 (A), occludin (B), Muc2 (C), Muc5A (D), and HBD-3 (E) resulted in overexpression after the stimulation with butyrate. Butyrate treatment significantly reduced HDAC activity in a dose-dependent manner in Caco-2/HT-29 cells (F). Data represent the median with range of 2 independent experiments, each performed in triplicate. Data were analyzed using the unpaired *t* test. HBD-3, β -defensin 3; Muc2, mucin 2; Muc5AC, mucin 5AC; TSA, trichostatin A; ZO-1, zonula occludens 1. * $P < .05$ NT vs all doses; # $P < .05$ 0.75 vs 0.5; ° $P < .05$ 0.75 vs 1




FIGURE 5 Evaluation of direct immunoregulatory action of HM butyrate on human peripheral blood mononuclear cells (PBMCs): Th2/Th1 and IL-10 response and evaluation of FoxP3 expression. A, PBMCs from children with IgE-mediated FA were stimulated with butyrate HM median concentration (0.75 mM) or with BLG, OVA, and PN (100 μ L/well) in the presence or in the absence of butyrate HM median concentration for 24 h. BLG, OVA, and PN induced a significant increase in IL-4 (A), IL-5, and IL-13 (C) production, but the presence of 0.75 mM butyrate significantly reduced the release of these Th2 cytokines. Butyrate alone or in the presence of specific allergen stimulated, at the same dose, IL-10 (D) and IFN- γ (E) production and FoxP3 expression (F), through a demethylation of respective gene (G, H, I) in CD4+ T cells purified from stimulated PBMCs from children with IgE-mediated FA. (L) Butyrate treatment significantly reduced HDAC activity in a dose-dependent manner in PBMCs. Data represent the median with range of 2 independent experiments, each performed in triplicate. Data were analyzed using the unpaired *t* test. BLG, β -lactoglobulin; NT, untreated cells; OVA, ovalbumin; PN, peanut extracts. **P* < .05; ***P* < .01

effective dose for the production of the HBD-3 by human enterocytes (Figure 4, panel E).

Butyrate exhibits also HDAC inhibitory activity, in fact it induces histone acetylation in multiple cell types, and through HDAC inhibition, it elicits its stimulatory action on mRNA expression.^{36,37} To assess whether butyrate acts as an HDAC inhibitor in human enterocytes, we analyzed its effect compared with trichostatin A (TSA), a well-established HDAC inhibitor. Butyrate treatment significantly reduced HDAC activity in a dose-dependent manner in human enterocytes, with the maximal effect observable at 0.75 mM (Figure 4, panel F).

3.5 | Evaluation of direct immunoregulatory action of butyrate on human peripheral blood mononuclear cells

To assess the efficacy of butyrate to drive tolerogenic mechanisms, we tested its effect on PBMCs derived from healthy donors or children affected by FA.

To test the system, we performed a proliferation test to evaluate whether 0.75 mM butyrate affects cell viability. Our data showed that butyrate, at this concentration, significantly increased the percentage of cell viability (Figure S1, panel A). Detection of apoptosis demonstrated that the mortality cell rate after treatment with butyrate was comparable to the control (Figure S1, panel B).

From time-course and dose-response experiments on PBMCs from healthy children to define the stimulation time and the useful dose of butyrate, we measured IL-10 production. We found that IL-10 release increased at a minimum dose of 0.5 mM of butyrate with a maximal effect at 0.75 mM after 24 hours of incubation. No modulation was observed for the production of IL-4, IL-5, IL-13, and IFN- γ (data not shown).

We analyzed the effect on PBMCs from children affected by IgE-mediated cow's milk allergy, hen's egg allergy, or peanut allergy. Stimulation with BLG, OVA, or PN resulted in a significant increase in Th2 cytokine production: IL-4, IL-5, and IL-13, and the




FIGURE 6 Evaluation of direct immunoregulatory action of HM butyrate on human peripheral blood mononuclear cells (PBMCs): modulation of mono-dendritic cell expression. PBMCs from children with IgE-mediated FA were stimulated with butyrate HM median concentration (0.75 mM) or with specific allergen (BLG, OVA, PN) (100 μ L/well of each allergen) in the presence or in the absence of butyrate for 48 h (A-B). CD45hi CD14+ monocytes were stained with flow cytometric markers CD206+ or CD86+ to discern the CD206 M2 type from CD86 M1 type of total monocytes. A representative dot plot panel (left panel) is presented. The graph on the right reports the mean \pm SD of ratios of M1 vs M2 peripheral monocytes (CD86/CD206 ratio) from different FA patients (ANOVA; *** P < .001 vs CTRL) (B). Purified CD14+ monocytes from IgE-mediated FA were cultured with regular medium containing GM-CSF (50 ng/mL) and IL-4 (1000 U/mL), with or without butyrate HM median concentration (0.75 mM). After 7 d, cells were collected, stained with the reported antibodies, and analyzed by flow cytometry (C-E). Representative example of dot plots of iDCs generated in the presence or in the absence of butyrate (C). The bars graph reports mean and standard deviation of % of CD14-CD1a+ from independent experiments using different IgE-mediated FA (ANOVA; *** P < .001 vs CTRL). (D). Immature DCs were collected and exposed to LPS-activating stimulus (1 μ g/mL). After 24 h, cells were stained for CD86 maturation marker. Bar graphs report the percentage of positive cells for the indicated markers in gated viable CD14-CD1a+ cells (ANOVA; *** P < .001 vs CTRL) (E). Phenotypical characterization of iDCs generated in the presence or in the absence of 0.75 mM of butyrate for 7 d in healthy subjects (left panel) and in IgE-mediated FA (right panel). Bar graph reports mean and standard deviation of % of CD11b+ CD103+ from independent experiments using IgE-mediated FA (ANOVA; *** P < .001 vs CTRL). (F-G). Butyrate-DC had no effect on regulatory cell differentiation. Naïve CD4+ T cells from IgE-mediated FA were cultured with immature or mature DCs generated in the presence of butyrate at 1:10 DC:T ratio. After being cultured for 5 d, cells were collected. CD4+CD25+CD127 dim⁺ Tregs were identified and enumerated with a flow cytometer (H). The bar graphs report the percentage of positive cells for the indicated markers

unchanged expression of IL-10, IFN- γ , and FoxP3, respectively. Conversely, the treatment with 0.75 mM butyrate or its co-incubation with the specific allergen caused an inhibition in Th2 cytokine production and a significant up-regulation of IL-10, IFN- γ and FoxP3 expression (Figure 5, panels A-F).

As shown in Figure 5 (panels G-H), the treatment with 0.75 mM butyrate alone and in the presence of specific allergen induced the production of IL-10 and IFN- γ , through a demethylation of respective gene promoters. This effect paralleled with a modulation of FoxP3 demethylation and its expression (Figure 5,




FIGURE 7 Evaluation of direct immunoregulatory action of HM butyrate on human peripheral blood mononuclear cells (PBMCs); effect on CD4+ T-cell subsets. Butyrate directly affects the Treg generation. Naïve CD4+ T cells were collected from healthy controls and from IgE-mediated FA children and were maintained in culture with or without 0.75 mM of butyrate. After 5 d, cells were collected. CD4+CD25+CD127 dim/neg Tregs were identified and enumerated with a flow cytometer. The bar graphs on the right report the percentage of positive cells for the indicated markers (ANOVA; **P* < .05 vs CTRL) (A-B). Butyrate-DC had an effect on TCD4+ cell differentiation. Naïve CD4+ T cells from IgE-mediated FA patients and healthy controls were cultured with DCs generated in the presence of butyrate at 1:10 DC:T ratio. After 5 d, cells were collected and stained with the indicated markers prior to FACS analysis. CD45RA and CCR7 markers allow the definition of most peculiar subsets among CD4+ T-cell compartment including memory effector (TEM; CD45RA-CCR7), effector memory RA (TEMRA; CD45RA+CCR7-), naïve (TN; CD45RA+CCR7+), and central memory (TCM; CD45RA-CCR7+) T cells (C-E). Representative example of dot plots of TCD4+ cells from control and IgE-mediated FA subjects after autologous T:DC co-culture (D-E). The bar graphs report the percentage of positive cells for the indicated markers in CD4+ gated viable cells (ANOVA; **P* < .05, ***P* < .01, ****P* < .001 vs CTRL)

panels I and F). We demonstrated that the effect of HM butyrate on gene methylation was via HDAC inhibitor (Figure 5, panel J).

Subsequently, we stimulated PBMCs from healthy children and IgE-mediated CMA patients, with BLG in the absence, or in the presence of 0.75 mM butyrate to verify whether this SCFA could

shift the pro-inflammatory (M1 state) phenotype of FA monocytes toward an anti-inflammatory, regulatory, and protective response state (M2 state). Specifically, polarization is a candidate biomarker of disease-related inflammatory status, the M1/M2 profile was assessed measuring CD86/CD206 ratio as a marker of the relative proportion of M1 vs M2 cells in gated CD14⁺ monocytes from FA subjects stimulated with specific allergen, in the absence or presence of butyrate. Interestingly, flow cytometry analysis of CD86/CD206 indicated that HM butyrate increased M1 monocytes (Figure 6, panels A-B), and similar results were observed in children with CMA affected by IgE-mediated hen's egg allergy or peanut allergy (data not shown).

We subsequently investigated HM butyrate's ability to affect the differentiation of iMoDCs from IgE-mediated FA patients. We generated iMoDCs and treated them with butyrate immediately before incubation with GM-CSF and IL-4. After 7 days of incubation, the expression of CD1a decreased (Figure 6, panel C) in the butyrate-treated cells compared with the untreated cells.

However, although butyrate partially inhibited the differentiation process and reduced the yield of conventional CD1a⁺ iDCs, there was a high expression of CD86, a DC maturation marker, in the cells from patients with IgE-mediated FA (Figure 6, panel D). Conversely, iDCs from both IgE-mediated FA patients and healthy subjects, generated in the presence of butyrate, expressed higher levels of CD103 and CD11b on their surfaces, indicating the tendency of butyrate-exposed DCs to acquire a tolerogenic phenotype (Figure 6, panels E-G). Starting from the evidence that CD103⁺CD11b⁺ DCs were able to induce the differentiation of CD4⁺ naïve T cells toward a tolerogenic phenotype *in vitro* and *in vivo*, we next assessed the function of butyrate on Treg differentiation. As first, butyrate-exposed DCs from both the healthy and CMA subjects were tested for their ability to induce the differentiation of naïve CD4⁺ T cells after 7 days of co-culture. In this condition, a comparable percentage of CD25⁺CD127⁻/dim Tregs was found in the untreated and butyrate-treated groups both in the presence and in the absence of BLG stimulus, indicating that butyrate-DCs are inefficient to induce the differentiation of Tregs *in vitro* (Figure 6, panel H), and suggesting the potential role of a peculiar chemokines milieu obtainable only in the *in vivo* setting. Conversely, when directly added as a stimulus to T-cell culture, butyrate itself displayed efficient regulation of the differentiation of naïve CD4⁺ T cells to acquire a regulatory phenotype in healthy controls and to a greater extent in FA patients.

Specifically, the stimulation with 0.75 mM of butyrate of CD4⁺ naïve T cells elicited an increase in the number of CD25⁺CD127⁻/dim Tregs in IgE-mediated FA patients (Figure 7, panels A-B).

Finally, we investigated whether butyrate-DC could affect the generation of other additional subsets of CD4⁺ T cells. A reduction in the mean percentages of effector memory T cells (TEM; CD45RA⁺CCR7⁻) and effector memory RA T cells (TEMRA; CD45RA⁺CCR7⁻) after autologous T:DC co-culture was observed in IgE-mediated FA patients compared with healthy controls (Figure 7, panel C). A further decrease was observed after allergen stimulation in IgE-mediated FA patients compared with healthy controls (Figure 7,

panels D-E). The administration of 0.75 mM butyrate restored the compartment of both TEM and TEMRA of allergen-stimulated CD4⁺ naïve T cells from IgE-mediated FA patients compared with healthy controls (Figure 7, panels D-E).

4 | DISCUSSION

The actual picture emerging from the literature suggests a crucial role for dietary fiber-fermenting bacteria that, through the production of butyrate, modulate gut barrier function and support the establishment of a tolerogenic environment by inducing Tregs and inhibiting pro-inflammatory DC functions.^{38,39}

In a large cohort of healthy lactating women, we demonstrated that butyrate is present in HM at an effective concentration that is able to modulate a wide range of tolerogenic mechanisms. Data on the concentration of butyrate in HM are conflicting. Discrepancies in butyrate values in HM, as well as in other biological samples, could derive not only from the analytical method used,⁴⁰ but also by other factors including the extraction method, the features of the study population, and the breast milk sampling and storing procedures. However, the HM butyrate levels observed in our study are well in line with those reported by recent studies where the samples were analyzed by two different techniques, ¹H-nuclear magnetic resonance spectroscopy (NMR) and GC-MS.^{40,41}

Our findings highlight the role of butyrate as a pivotal HM compound that exerts a wide modulation of immune tolerance mechanisms. Data from animal model experiments demonstrate that butyrate at 0.75 mM could drive a nonspecific protection against the most common forms of FA. A positive modulation of anaphylactic symptom score, body temperature, and Th1/Th2 cytokines expression was demonstrated in animals receiving butyrate. We found an enhancement in IL-10 expression, a major immune-regulatory cytokine that maintains mucosal homeostasis and limits excessive immune response against dietary antigens.⁴² In this light, recent evidence suggests that butyrate, but not acetate or propionate, is able to modulate Th2 cytokines production and to ameliorate type 2 innate lymphoid cell (ILC2)-driven airway hyper-reactivity and inflammation in murine model of asthma.⁴³ In addition, it has been demonstrated that high fiber consumption increased SCFAs level and led to an increase in tolerogenic CD103⁺DC activity and Treg differentiation in peanut allergy mouse model.⁴⁴ Emerging data show that intraluminal butyrate is rapidly absorbed along the gastrointestinal tract.⁴⁵⁻⁴⁹ Thus, it is possible to speculate that butyrate could modulate the immune tolerance network both in the gastrointestinal tract and at the systemic level. In addition, it has been demonstrated that increasing intraluminal butyrate through dietary supplementation could exert a beneficial effect on gut microbiota increasing the abundance of butyrate-producing bacteria.^{47,50,51} The involvement of the liver in FA is emerging.⁵² Studies have suggested that the liver could act as a source of helper CD4⁺ T cells and play a role in IgE response to dietary antigens.⁵³

Mitochondrial dysfunction and elevated ROS have been reported in allergic diseases.⁵⁴⁻⁵⁷ We recently reported a significant

correlation between hepatic mitochondrial dysfunction and specific IgE, IL-5, and IL-13 mRNA expression in the peanut allergy animal model.³³ Here, we demonstrated that 0.75 mM butyrate is able to significantly prevent mitochondrial dysfunction in all the three FA models, reducing H₂O₂ release and SOD activity, and reactivating the aconitase enzyme.

Food allergy depends on a breakdown of the immune tolerance network.⁵⁸ This network is composed of immune and non-immune mechanisms.⁵ Among nonimmune mechanisms, epithelial mucus thickness and permeability are considered very relevant in preserving immune tolerance.⁵⁹ Loss of epithelial integrity in the gut increases antigen uptake and promotes Th2-type allergic response by activation of ILC2s, mast cells, basophils, and DCs.⁶⁰ We found that HM median concentration of butyrate is able to up-regulate TJ proteins expression. A significant increase in Muc2, Muc5AC expression, and mucus layer thickness was also observed after stimulation of human enterocytes with 0.75 mM butyrate. Similarly, it has been demonstrated that butyrate differently stimulates the expression of various mucin genes in the colon, with maximum effects on Muc2 expression.⁶¹ The mucus layer does not merely form a nonspecific physical barrier, but also constrains the immunogenicity of gut antigens by delivering tolerogenic signals.³⁴ Interestingly, it has been shown that Muc2 enhances IL-10 secretion in CD1c⁺ DCs and increases DC transcription and secretion of transforming growth factor- β 1 (TGF- β 1), a SMAD-signaling cytokine that helps the induction of Tregs by tolerogenic CD103⁺ DCs, stimulating immune tolerance.³⁴ Finally, Muc2^{-/-} mice restored immune tolerance when gavaged with OVA in the presence of exogen Muc2.⁶²

Among immune mechanisms, we found that butyrate is able also to stimulate the immune tolerance, enhancing the HBD-3 production by human enterocytes, involved in induction of FoxP3⁺ T cells.³⁵

According to previous findings,^{13,63} we demonstrated that median HM concentration of butyrate inhibits HDAC activity. It has been demonstrated that this action leads to transcriptional activation, with increased access of basal transcription factors and RNA polymerase II to the promoter region.⁶⁴ Whether the effect of butyrate is due to direct acetylation of permeability and mucus-related genes or indirectly through transcriptional activation/repression of other targets, that could enhance the expression of these genes, warrants further investigation.

Immune system cells exert a pivotal role in regulating a state of active nonresponsiveness to food antigens.⁶⁵ For this reason, we explored the direct effects of 0.75mM butyrate on PBMCs from FA children. In agreement with previous findings, we found that butyrate inhibits Th2 cytokines production.⁴⁴ This was not due to a change in the methylation status of the genes, but most likely through the modulation of the transcriptional activation/repression of other genes that can alter the expression of Th2-related genes.⁴⁴ In contrast, we observed that HM median butyrate concentration stimulated tolerogenic cytokine production and FoxP3 expression through a demethylation of the respective genes. It has

been demonstrated that the inhibition of HDAC 6 and HDAC 9 is responsible for the increase in FoxP3 gene expression and the increase in Tregs.⁶⁶ Acetylation of FoxP3 is an important post-translational mechanism that affects FoxP3 abundance, because it protects FoxP3 proteasomal degradation.⁶⁷ This is a signature mechanism of action of several HDACs in Tregs.⁶⁸⁻⁷⁰ Studies have suggested a direct effect of butyrate as HDAC inhibitor in the activation of Tregs.⁷⁹ Treatment of naïve T cells with butyrate enhances histone H3 acetylation in the conserved noncoding sequence regions of the FoxP3 locus (TSDR), suggesting a possible mechanism for how butyrate regulates the differentiation of Tregs.⁸ The switch toward a tolerogenic response by butyrate may be partly mediated by its action also on myeloid compartment because mono-macrophages exhibit a sliding scale of functional heterogeneity ranging from pro-inflammatory M1 state to anti-inflammatory M2 state.⁷¹ Flow cytometry analysis of PBMCs from IgE-mediated FA patients demonstrated that butyrate at median concentration found in HM increased the M1/M2 ratio of peripheral monocytes. In the context of allergy, recent studies highlighted that the inflammatory monocytes can differentiate into anti-inflammatory M2-type macrophages, which in turn dampen allergic inflammation.⁷¹ FoxP3+CD4+ Tregs are central in the maintenance of immune homeostasis and tolerance throughout the body, particularly in the gut. We found that butyrate, at a median HM concentration, elicited an increase in the number of tolerogenic CD103+CD11b+ DCs and CD25+CD127-/dim Tregs, as previously suggested by others.^{7,9,72,73}

Following antigen encounter and subsequent resolution of the immune response, a single CD4+ naïve T cell is able to generate also multiple subsets of memory T cells with different phenotypic and functional properties. CD45RA and CCR7 markers allow the definition of most peculiar subsets among CD4+ T-cell compartment including CD45RA-CCR7 TEM CD45RA+CCR7-TEMRA, naïve (TN; CD45RA+CR7+), and central memory (TCM; CD45RA-CCR7+) T cells.⁷⁴⁻⁷⁷ We demonstrated that butyrate was able to restore TEM and TEMRA of IgE-mediated FA patients. As effector memory T cells have been observed to play a potential role in immune diseases,^{74,75} the fine-tuning of CD4+ T-cell differentiation by butyrate may be a new intriguing mechanism of its protective action.

This work had strengths and limitations. We determined HM butyrate concentration in a large cohort of healthy lactating women, and we provided evidence about multiple regulatory actions on tolerogenic mechanisms elicited by butyrate HM median concentration. The study limitations are related to the fact that we did not explore the effect of butyrate against other forms of FA or investigate the source of HM butyrate. The origin of HM butyrate remains to be elucidated.

Recent evidence suggests a pivotal contribution by mammalian gland/HM microbiota in butyrate production deriving from metabolism of human milk oligosaccharides.⁷⁸⁻⁸³ Another limitation of our study is that HM contains a wide range of bioactive factors, in addition to butyrate, that are able to shape immune system function,⁸⁴ and we did not evaluate whether the effect of butyrate could be additive to other HM biofactors.

In conclusion, a powerful HM compound has been defined. Altogether, the results obtained in this study could explain the actual conflicting data on the efficacy of HM in preventing FA. The efficacy of HM could be based on the content of selected immunoregulatory compounds, such as butyrate. Increasing the concentration of such compound in HM, by modulating the maternal diet and lifestyle factors, could be an effective strategy to increase the protective role of HM against FA. At the same time, our data reveal the possibility of using butyrate as a supplement in the formulas for nonbreastfed infants to protect from FA in early life.

ACKNOWLEDGMENTS

This work was supported in part by a grant of the Italian Ministry of Health (PE-2011-02348447) devoted to the Department of Translational Medical Science of the University "Federico II" of Naples and by a grant of the Cariplo Foundation (no. 2016-0874), the Italian Ministry of Health (grant RF-2011-02348194), and the Italian Ministry of the University and Scientific Research (PRIN-20157ATSLF_009) devoted to the University of Salerno. Dr E. Ciaglia was also supported by a fellowship from Umberto Veronesi Foundation (FUV 2017 cod.1072, FUV 2018 cod.2153, FUV 2019 cod.2798). However, the Italian Ministry of Health, the Italian Ministry of the University and Scientific Research, the Cariplo Foundation, and the Umberto Veronesi Foundation had no influence on (a) the study design; (b) the collection, analysis, and interpretation of the data; (c) the writing of the manuscript; or (d) the decision to submit the manuscript for publication. We thank Prof. C. Nagler for the kind support in providing peanut extracts for the experiments. We thank all the mothers who contributed enthusiastically to the research and all healthy subjects and FA patients who participated in the study.

CONFLICT OF INTEREST

The authors have no other conflict of interests that are directly relevant to the content of this manuscript, which remains their sole responsibility.

AUTHOR CONTRIBUTIONS

RBC, LP, and RN designed the study, coordinated the research team, and wrote the first draft of this report. CDC, MDC, AP, AA, LV, and GDG were responsible for the study subjects and evaluated their health status. LP, EC, CDC, RR, GT, RA, FM, AA, and CB conducted the laboratory experiments. LP, RN, GT, and EC performed the statistical analysis and data interpretation. All of the authors revised and approved the final version of this article.

ORCID

Lorella Paparo  <https://orcid.org/0000-0002-5562-1408>

Rita Nocerino  <https://orcid.org/0000-0003-4681-546X>

Rosita Aitoro  <https://orcid.org/0000-0002-8518-2047>

Roberto Berni Canani  <https://orcid.org/0000-0002-5169-9574>

REFERENCES

- Yu W, Freeland DMH, Nadeau KC. Food allergy: immune mechanisms, diagnosis and immunotherapy. *Nat Rev Immunol*. 2016;16:751–765.
- Sicherer SH, Sampson HA. Food allergy: epidemiology, pathogenesis, diagnosis, and treatment. *J Allergy Clin Immunol*. 2014;133:291–307.
- Ho HE, Bunyavanich S. Role of the microbiome in food allergy. *Curr Allergy Asthma Rep*. 2018;18:27.
- Feehley T, Plunkett CH, Bao R, et al. Healthy infants harbor intestinal bacteria that protect against food allergy. *Nat Med*. 2019;25:448–453.
- Berni Canani R, Paparo L, Nocerino R, et al. Gut microbiome as target for innovative strategies against food allergy. *Front Immunol*. 2019;10:191.
- Nowak-Węgrzyn A, Chatchatee P. Mechanisms of tolerance induction. *Ann Nutr Metab* 2017;70(Suppl. 2):7–24.
- Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T cell generation. *Nature* 2013;504:451–455.
- Furusawa Y, Obata Y. Commensal microbe-derived butyrate induces differentiation of colonic regulatory T cells. *Nature* 2013;504:446–450.
- Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic T reg cell homeostasis. *Science* 2013;341:569–573.
- Peng L, Li Z-R, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. *J Nutr*. 2009;139:1619–1625.
- Burger-van Paassen N, Vincent A, Puiman P, et al. The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection. *Biochem J*. 2009;420:211–219.
- Sun M, Wei WU, Liu Z, Cong Y. Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases. *J Gastroenterol*. 2017;52:1–8.
- Tan J, McKenzie C, Vuillermin P, et al. Dietary fiber and bacterial SCFA enhance oral tolerance and protect against food allergy through diverse cellular pathways. *Cell Rep*. 2016;15:2809–2824.
- Greer FR, Sicherer SH, Burks AW. The effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, hydrolyzed formulas, and timing of introduction of allergenic complementary foods. *Pediatrics*. 2019;143(4):e20190281.
- Garcia-Larsen V, Ierodiakonou D, Jarrold K, et al. Diet during pregnancy and infancy and risk of allergic or autoimmune disease: a systematic review and meta-analysis. *PLoS Med*. 2018;15:e1002507.
- Muraro A, Halken S, Arshad SH, et al. EAACI food allergy and anaphylaxis guidelines. *Prim Prev Food Allergy*. 2014;69:590–601.
- Hoddinott P, Tappin D, Wright C. Breast feeding. *BMJ*. 2008;336:881–887.
- Jiang Z, Liu Y, Zhu Y, et al. Characteristic chromatographic fingerprint study of short-chain fatty acids in human milk, infant formula, pure milk and fermented milk by gas chromatography-mass spectrometry. *Int J Food Sci Nutr*. 2016;67:632–640.
- Zijlstra JB, Beukema J, Wolthers BG, Byrne BM, Groen A, Dankert J. Pretreatment methods prior to gaschromatographic analysis of volatile fatty acids from faecal samples. *Clin Chim Acta* 1977;78:243–250.
- Aitoro R, Simeoli R, Amoroso A, et al. Extensively hydrolyzed casein formula alone or with Lrhamnosus GG reduces b-lactoglobulin sensitization in mice. *Pediatr Allergy Immunol*. 2017;28:230–237.
- Berni Canani R, Paparo L, Nocerino R, et al. Differences in DNA methylation profile of Th1 and Th2 cytokine genes are associated with tolerance acquisition in children with IgE-mediated cow's milk allergy. *Clin Epigenetics* 2015;7:38.
- Paparo L, Nocerino R, Cosenza L, et al. Epigenetic features of FoxP3 in children with cow's milk allergy. *Clin Epigenetics*. 2016;8:86.
- D'Argenio V, Del Monaco V, Paparo L, et al. D'Alessio Fet al Altered miR-193a- 5p expression in children with cow's milk allergy. *Allergy* 2018;73:379–386.

24. Atarashi K, Tanoue T, Ando M, et al. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. *Cell* 2015;163:367–380.
25. Hartree EF. Determination of protein: a modification of the Lowry method that gives a linear photometric response. *Anal Biochem.* 1972;48:422–427.
26. Hausladen A, Fridovich I. Measuring nitric oxide and superoxide: rate constants for aconitase reactivity. *Methods Enzymol.* 1996;269:37–41.
27. Barja G. Mitochondrial free radical production and aging in mammals and birds. *Ann NY Acad Sci.* 1998;854:224–238.
28. Flohè L, Otting F. Superoxide dismutase assay. *Methods Enzymol.* 1984;105:93–104.
29. Pan F, Han L, Zhang Y, Yu Y, Liu J. Optimization of Caco-2 and HT29 co-culture in vitro cell models for permeability studies. *Int J Food Sci Nutr.* 2015;66:680–685.
30. Paparo L, Aitoro R, Nocerino R, Fierro C, Bruno C, Berni CR. Direct effects of fermented cow's milk product with *Lactobacillus paracasei* CBA L74 on human enterocytes. *Benef Microbes.* 2018;9:165–172.
31. Giardino Torchia ML, Ciaglia E, Masci AM, et al. Dendritic cells/natural killer cross-talk: a novel target for human immunodeficiency virus type-1 protease inhibitors. *PLoS One* 2010;5:e11052.
32. Ali TH, Pisanti S, Ciaglia E, et al. Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. *Nat Commun.* 2014;5:5639.
33. Trinchese G, Paparo L, Aitoro R, et al. Hepatic mitochondrial dysfunction and immune response in a murine model of peanut allergy. *Nutrients* 2018;10(6):744.
34. Shan M, Gentile M, Yeiser JR, et al. Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. *Science* 2013;342:447–453.
35. Navid F, Boniotti M, Walker C, et al. Induction of regulatory T cells by a murine β -defensin. *J Immunol.* 2012;188:735–743.
36. Davie J. Inhibition of histone deacetylase activity by butyrate. *J Nutr.* 2003;133:2485S–S2493.
37. Nguyen NH, Morland C, Gonzalez SV, et al. Propionate increases neuronal histone acetylation, but is metabolized oxidatively by glia. Relevance for propionic academia. *J Neurochem.* 2007;101:806–814.
38. Kemter AK, Nagler CR. Influences on allergic mechanisms through gut, lung, and skin microbiome exposures. *J Clin Invest.* 2019;130:1483–1492.
39. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. *Cell* 2016;165:1332–1345.
40. Prentice PM, Schoemaker MH, Vervoort J, et al. Human milk short-chain fatty acid composition is associated with adiposity outcomes in infants. *J Nutr.* 2019;149:716–722.
41. Dai X, Yuan T, Zhang X, et al. Short-chain fatty acid (SCFA) and medium-chain fatty acid (MCFA) concentrations in human milk consumed by infants born at different gestational ages and the variations in concentration during lactation stages. *Food Funct.* 2020;11:1869–1880.
42. Ochi T, Feng Y, Kitamoto S, et al. Diet-dependent, microbiota-independent regulation of IL-10-producing lamina propria macrophages in the small intestine. *Sci Rep.* 2016;6:27634.
43. Thio CL, Chi PY, Lai AC, Chang YJ. Regulation of type 2 innate lymphoid cell dependent airway hyperreactivity by butyrate. *J Allergy Clin Immunol.* 2018;142:1867–1883.
44. Tan J, McKenzie C, Vuillermin P, et al. Dietary fiber and bacterial SCFA enhance oral tolerance and protect against food allergy through diverse cellular pathways. *Cell Rep* 2016;15:2809–2824.
45. Schmitt MG, Soergel KH, Woodet CM. Absorption of short chain fatty acids from the human jejunum. *Gastroenterology* 1976;70:21.
46. Guilloteau P, Martin L, Eeckhaut V, Ducatelle R, Zabielski R, Van Immerseel F. From the gut to the peripheral tissues: the multiple effects of butyrate. *Nutr Res Rev.* 2010;23:366.
47. Jimenez Janelle A, Uwiera TC, Abbott DW, Uwiera RRE, Douglas IG. Butyrate supplementation at high concentrations alters enteric bacterial communities and reduces intestinal inflammation in mice infected with *Citrobacter rodentium*. *mSphere.* 2017;2(4):e00243.
48. Ruppin H, Bar-Meir S, Soergel KH, Wood CM, Schmitt MG. Absorption of short-chain fatty acids by the colon. *Gastroenterology* 1980;78:1500–1507.
49. Bergman EN. Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. *Physiol Rev.* 1990;70:567–590.
50. Zhou DA, Pan Q, Xin F-Z, et al. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier. *World J Gastroenterol.* 2017;23:60–75.
51. Wu W, Xiao Z, An W, Dong Y, Zhang B. Dietary sodium butyrate improves intestinal development and function by modulating the microbial community in broilers. *PLoS One* 2018;13:e0197762.
52. Mitsui M, Shoda T, Natsume O, et al. Factors associated with development of food allergy in young children after liver transplantation: a retrospective analysis of 10 years' experience. *J Allergy Clin Immunol Pract.* 2017;5:1698–1706.
53. Watanabe T, Katsukura H, Shirai Y, et al. Helper CD4+ T cells for IgE response to a dietary antigen develop in the liver. *J Allergy Clin Immunol.* 2003;111:1375–1385.
54. Aguilera-Aguirre L, Bacsi A, Saavedra-Molina A, Kurosky A, Sur S, Boldogh I. Mitochondrial dysfunction increases allergic airway inflammation. *J Immunol.* 2009;183:5379–5387.
55. Kim SR, Kim DI, Kim SH, et al. NLRP3 inflammasome activation by mitochondrial ROS in bronchial epithelial cells is required for allergic inflammation. *Cell Death Dis.* 2014;5:e1498.
56. Iyer D, Mishra N, Agrawal A. Mitochondrial function in allergic disease. *Curr Allergy Asthma Rep.* 2017;17:29.
57. Qi S, Barnig C, Charles A-L, et al. Effect of nasal allergen challenge in allergic rhinitis on mitochondrial function of peripheral blood mononuclear cells. *Ann Allergy Asthma Immunol.* 2017;118:367–369.
58. Sicherer SH, Sampson HA. Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention, and management. *J Allergy Clin Immunol.* 2018;141:41–58.
59. Pelaseyed T, Bergström JH, Gustafsson JK, et al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. *Immunol Rev.* 2014;260:8–20.
60. Hammad H, Lambrecht B. Barrier epithelial cells and the control of type 2 immunity. *Immunity* 2015;43:29–40.
61. Chen G, Ran X, Li B, et al. Sodium butyrate inhibits inflammation and maintains epithelium barrier integrity in a TNBS-induced inflammatory bowel disease mice model. *EBioMedicine.* 2018;30:317–325.
62. Tadesse S, Corner G, Dhima E, et al. MUC2 mucin deficiency alters inflammatory and metabolic pathways in the mouse intestinal mucosa. *Oncotarget.* 2017;8:71456–71470.
63. Paparo L, Di Costanzo M, Di Scala C, et al. The influence of early life nutrition on epigenetic regulatory mechanisms of the immune system. *Nutrients.* 2014;6:4706–4719.
64. Ito K, Adcock IM. Histone acetylation and histone deacetylation. *Mol Biotechnol.* 2002;20:99–106.
65. Chinthrajah RS, Hernandez JD, Boyd SD, Galli SJ, Nadeau KC. Molecular and cellular mechanisms of food allergy and food tolerance. *J Allergy Clin Immunol.* 2016;137:984–997.
66. Beier UH, Wang L, Han R, Akimova T, Liu Y, Hancock WW. Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms. *Sci Signal.* 2012;5:ra45.
67. van Loosdregt J, Brunen D, Fleskens V, Pals CE, Lam EW, Coffey PJ. Rapid temporal control of Foxp3 protein degradation by sirtuin-1. *PLoS One* 2011;6:e19047.

68. Tao R, de Zoeten EF, Özkaynak E, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. *Nat Med*. 2007;13:1299–1307.
69. Li B, Samanta A, Song X, et al. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. *Proc Natl Acad Sci USA* 2007;104:4571–4576.
70. Tao R, de Zoeten EF, Ozkaynak E, et al. Histone deacetylase inhibitors and transplantation. *Curr Opin Immunol*. 2007;19:589–595.
71. Egawa M, Mukai K, Yoshikawa S, et al. Inflammatory monocytes recruited to allergic skin acquire an anti-inflammatory M2 phenotype via basophil-derived interleukin-4. *Immunity* 2013;38:570–580.
72. Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. The who's who of T-cell differentiation: human memory T-cell subsets. *Eur J Immunol*. 2013;43:2797–2809.
73. Appay V, Zaunders JJ, Papagno L, et al. Characterization of CD4(+) CTLs ex vivo. *J Immunol*. 2002;168:5954–5958.
74. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature* 1999;401:708–712.
75. Sani MM, Ashari NSM, Abdullah B, et al. Reduced CD4+ terminally differentiated effector memory T cells in moderate-severe house dust mites sensitized allergic rhinitis patients. *Asian Pac J Allergy Immunol*. 2018;37:138–146.
76. Shamji MH, Bellido V, Scadding GW, et al. Effector cell signature in peripheral blood following nasal allergen challenge in grass pollen allergic individuals. *Allergy* 2015;70:171–179.
77. Wambre E, Bonvalet M, Bodo VB, et al. Distinct characteristics of seasonal (Bet v 1) vs perennial (Der p 1/Der p 2) allergen-specific CD4(+) T cell responses. *Clin Exp Allergy*. 2011;41:192–203.
78. Moossavi S, Sepehri S, Robertson B, et al. Composition and variation of the human milk microbiota are influenced by maternal and early-life factors. *Cell Host Microbe*. 2019;25:324–335.
79. Moossavi S, Atakora F, Miliku K, et al. Integrated analysis of human milk microbiota with oligosaccharides and fatty acids in the CHILD cohort. *Front Nutr*. 2019;6:58.
80. McGuire MK, McGuire MA. Got bacteria? The astounding, yet not-so-surprising, microbiome of human milk. *Curr Opin Biotechnol*. 2017;44:63–68.
81. Walker WA, Iyengar RS. Breast milk, microbiota, and intestinal immune homeostasis. *Pediatr Res*. 2015;77:220–228.
82. Rautava S. Early microbial contact, the breast milk microbiome and child health. *J Dev Orig Health Dis*. 2016;7:5–14.
83. Munblit D, Verhasselt V. Allergy prevention by breastfeeding: possible mechanisms and evidence from human cohorts. *Curr Opin Allergy Clin Immunol*. 2016;16:427–433.
84. Ballard O, Morrow AL. Human milk composition: nutrients and bioactive factors. *Pediatr Clin North Am*. 2013;60:49–74.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Paparo L, Nocerino R, Ciaglia E, et al. Butyrate as bioactive human milk protective component against food allergy. *Allergy*. 2020;00:1–18. <https://doi.org/10.1111/all.14625>